Neuroimaging predictors of transition to psychosis—A systematic review and meta-analysis

Autor: Smieskova, R., Fusar-Poli, P., Allen, P., Bendfeldt, K., Stieglitz, R.D., Drewe, J., Radue, E.W., McGuire, P.K., Riecher-Rössler, A., Borgwardt, S.J.

Publikováno v: In Neuroscience and Biobehavioral Reviews 2010 34(8):1207-1222

Predicting conversion to clinically definite multiple sclerosis using machine learning on the basis of cerebral grey matter segmentations

Autor: Bendfeldt, K., Taschler, B., Gaetano, L., Madoerin, P., Kuster, P., Mueller-Lenke, N., Amann, M., Vrenken, H., Barkhof, F., Stefan Borgwardt, Kloeppel, S., Nichols, T. E., Suarez, G., Kappos, L., Edan, G., Freedman, M. S., Montalban, X., Hartung, H. -P, Pohl, C., Sandbrink, R., Wuerfel, J., Radue, E. -W, Sprenger, T.

Publikováno v: Multiple Sclerosis Journal
Multiple Sclerosis Journal, SAGE Publications, 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.498--499
Multiple Sclerosis Journal, 2015, 31st Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS), Barcelona, SPAIN, OCT 07-10, 2015, 21 (11), pp.498--499
ResearcherID

International audience; no abstract

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::28a5e70f398be14140514c33b3f90caf
https://hal-univ-rennes1.archives-ouvertes.fr/hal-01259385

Phase II study of oral fingolimod (FTY720) in multiple sclerosis: 3-year results

Autor: Comi, G, O'Connor, P, Montalban, X, Antel, J, Radue, Ew, Karlsson, G, Pohlmann, H, Aradhye, S, Kappos, L, Easton, Jd, Kesselring, J, Weinshenker, Bg, Laupacis, A, Zarbin, M, Calandra, T, Temkin, N, Dimarco, J, Hudson, Ld, Durcan, L, Bar Or, A, Duquette, P, Bernier, G, Freedman, M, Maclean, H, Costello, F, Gray, Ta, Hohol, M, Devonshire, V, Oger, J, Hashimoto, S, Sørensen, Ps, Datta, P, Faber Rod JC, Frederiksen, J, Knudsen, S, Petrenaite, V, Färkkila, M, Harno, H, Halavaara, J, Elovaara, I, Kuusisto, H, Palmio, J, Airas, L, Kaasinen, V, Laaksonen, M, Vermersch, P, Pelletier, J, Feuillet, L, Suchet, L, Mauch, E, Gunser, C, Oberbeck, K, Rieckmann, P, Buttmann, M, Klein, M, Ghezzi, A, Zaffaroni, M, Baldini, S, Mancardi, G, Cioli, F, Capello, E, Rodegher, M, Radaelli, M, Pozzilli, C, Onesti, Emanuela, Romano, Silvia, Czlonkowska, A, Litwin, T, Darda Ledzion, L, Kwiecinski, H, Golebiowski, M, Podlecka, A, Cunha, L, Sousa, L, Matias, F, Pedrosa, R, Almeida, M, Pena, Je, de Sá, J, Ferreira, J, Rosa, M, Arbizu, T, Carmona, O, Casado, V, Tintore, M, Pelayo, R, Arroyo, R, Bartolome, M, De las Heras, V, Casanova, B, Bosca, I, Fernandez, O, Leon, A, Romero, F, Izquierdo, G, Gamero, M, Garcia, Jm, Kuhle, J, Mehling, M, Achtnichts, L, Goebels, N, Skulina, C, Waskoenig, J, Bates, D, Nichols, P, Bendfeldt, K, de Vera, A, Gruenbauer, W.

Publikováno v: Multiple Sclerosis Journal
Multiple Sclerosis Journal, SAGE Publications, 2010, 16 (2), pp.197-207
Multiple Sclerosis Journal, 2010, 16 (2), pp.197-207

In a 6-month, placebo-controlled trial, oral fingolimod (FTY720) 1.25 or 5.0 mg, once daily, significantly reduced MRI inflammatory activity and annualized relapse rate compared with placebo in patients with relapsing multiple sclerosis (MS). The obj

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9942177c97a872608ed416d0e5b71a55
https://hal.archives-ouvertes.fr/hal-00617800

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.